Breaking News

Fresenius Kabi Launches Levofloxacin Freeflex IV

August 30, 2013

Designed for easier handling with enhanced safety

Fresenius Kabi USA has launched Levofloxacin in 5% Dextrose Injection in freeflex containers. Freeflex is designed for infusion solutions and has been marketed globally since 2005. Freeflex has multilayer polyolefin film that is PVC-free, plasticizer-free, non-DEHP, and is designed for easier handling with enhanced safety, and environmental performance.
 
Levofloxacin is a fluoroquinolone antibacterial indicated for use in the treatment of bacterial infections caused by susceptible bacteria, including pneumonia, bronchitis, skin infections, urinary tract infections, prostatitis and anthrax.
 
“The introduction of Levofloxacin using the freeflex technology expands our market leading anti-infective business with a ready to use formulation and provides customers with a new choice in serving their patients,” said John Ducker, president and chief executive officer of Fresenius Kabi USA.

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • The Western API Industry

    The Western API Industry

    Dr. Enrico T. Polastro, Arthur D. Little||January 28, 2016
    Temporary reprieve or lasting recovery?

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.